Maxim Pharmaceuticals Incorporated

Maxim Pharmaceuticals, Inc. is a global biopharmaceutical company with a strong pipeline of product candidates addressing cancer, hepatitis and other liver diseases. To date, Maxim has generated a significant body of clinical evidence supporting the Company’s multiple product candidates. Maxim’s research and development programs offer hope to patients by developing safe and effective therapeutic candidates that have the potential to extend survival while maintaining quality of life.

To execute its strategic mission, Maxim has attracted an experienced international management group and a team of employees dedicated to commercializing life-enhancing therapeutic candidates. Joining in its mission are world-renowned scientific and clinical investigators and major pharmaceutical development partners.



In addition to powerful technologies and experienced management, Maxim has strong financial resources and a pipeline that offers both near- and long-term commercialization opportunities.

Contact Details: 8899 University Center Lane San Diego CA 92122 United States of America Tel: (858) 453-4040 Fax: (858) 453-5005 Email: jmountzouris@maxim.com WWW: www.maxim.com/

Loading...

Recent Publications by Maxim Pharmaceuticals Incorporated:
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. This paper describes the design and synthesis of dipeptidyl N,N-dimethyl...	30th March, 2006	Maxim Pharmaceuticals, 6650 Nancy Ridge Drive, San Diego, CA 92121, USA.	J Med Chem. 2006 Feb 9;49(3):1198-201. DOI Direct Link
A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Transferrin receptor (TfR) has been shown to be significantly...	25th January, 2006	Maxim Pharmaceuticals, Inc., 6650 Nancy Ridge Drive, San Diego, CA 92121,	Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12095-100. Epub 2005 Aug 15. DOI Direct Link
Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions. As a continuation of our efforts to discover and develop the apoptosis...	24th December, 2005	Maxim Pharmaceuticals, Inc., 6650 Nancy Ridge Drive, San Diego, CA 92121,	Bioorg Med Chem Lett. 2005 Nov 1;15(21):4745-51. DOI Direct Link
Discovery and structure-activity relationship of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. We have identified...	28th September, 2005	Maxim Pharmaceuticals Inc., 6650 Nancy Ridge Drive, San Diego, CA 92121,	J Med Chem. 2005 Aug 11;48(16):5215-23. DOI Direct Link
Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice. The therapeutic efficacy in the treatment of metastatic cancer with high...	13th August, 2005	Maxim Pharmaceuticals, Inc., 8899 University Center Lane, Suite 400, San	Vascul Pharmacol. 2005 Mar;42(4):187-93. DOI Direct Link
→View more Maxim Pharmaceuticals Incorporated research publications.

BioNews Results for Maxim Pharmaceuticals Incorporated:
Lexicon Pharma Announced IBS Drug Had Positve Results In Clinical Trial (LXRX)	TradingMarkets:  Nov 13 2009 8:34PM Matching: maxim pharmaceuticals
MiddleBrook Pharmaceuticals Down 25.7% Since SmarTrend's Sell Recommendation	TradingMarkets:  Nov 13 2009 6:42PM Matching: maxim pharmaceuticals
H. D. Smith Appoints New Head of Generics Pharmaceuticals	Pharma Live:  Nov 13 2009 9:40PM Matching: maxim pharmaceuticals
AMAG Pharmaceuticals Up 7.2% Since SmarTrend's Buy Recommendation	TradingMarkets:  Nov 12 2009 8:35AM Matching: maxim pharmaceuticals
Acadia Pharmaceuticals Down 25.5% Since SmarTrend's Sell Recommendation	TradingMarkets:  Nov 12 2009 7:05PM Matching: maxim pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Maxim Pharmaceuticals Incorporated news.

Maxim Pharmaceuticals Incorporated Clinical Trials:
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Maxim Pharmaceuticals Incorporated Patents:
US Patent No.	Title
6893633	Methods and compositions for promoting the maturation of monocytes
6270781	Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
6245563	Enhanced activation of natural killer cells using an NK cell activator and hydrogen peroxide scavenger or inhibitor
6242473	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
6221893	Administration of histamine for therapeutic purposes
→View more Maxim Pharmaceuticals Incorporated patents.

Maxim Pharmaceuticals Incorporated (MAXM) Financial information Links from Barchart
MAXM Quote from from Barchart.com
MAXM Chart from from Barchart.com
MAXM Profile from from Barchart.com
MAXM Opinion from from Barchart.com
→View more Maxim Pharmaceuticals Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 805 times since April 2007, the link to the organisation's website has been followed 120 times

Recent Search Terms used to find this page: Maxim pharmaceuticals | pharmaceutical maxims | Maxim Pharmaceuticals Website | maxim transferrin patent | MAXIM PHARMACEUTICALS | maxim pharma | MAXIM PHARMACEUTICALS | maxim pharmaceutical | Maxim Pharmaceuticals | maxim pharmaceutical | .

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Maxim Pharmaceuticals Incorporated